课题基金 / 基金详情

Investigation of the hyporesponsive endotype to inform a precision medicine approach to sepsis

Investigation of the hyporesponsive endotype to inform a precision medicine approach to sepsis
低反应内型的研究为脓毒症的精准医学方法提供信息
批准号:
MR/V002503/1
负责人:
Julian Knight
金额:
$126.57万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --

项目摘要

项目成果

Julian Knight的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
What is being done? This research aims to improve the care of patients with sepsis by providing new insights into the nature and drivers of the individual patient sepsis response. Our long-term goal is to help to develop a precision medicine approach to sepsis that allows the right patients to be getting the right treatment at the right time.Why is this needed? Sepsis occurs when the body's response to infection is dysregulated and inappropriate. This results in organ failure and sometimes death. Why this happens in some people is unclear and we have no current treatments that target this. Sepsis is the most common reason for admission to medical intensive care units in the UK and has a high mortality of 25-30%. This is a major current problem for the NHS and sepsis is recognised by the WHO as a global health priority. How will this be done? In this research we will use our finding that levels of gene activity in blood cells can predict your type of sepsis response. We will study sepsis patients with a hyporesponsive state as these patients have the worse outcomes and may benefit from specific immunomodulatory therapies. Our first objective is to work out how doctors can identify such patients with confidence by measuring biomarkers in the blood. Our second objective is to determine how this response may change over time during the sepsis illness. Our third objective is to understand genetic predisposing factors. Our fourth objective is to understand the nature of white blood cell dysfunction in the hyporesponsive sepsis state. Our fifth objective is to work with doctors undertaking clinical trials to use knowledge of the hyporesponsive state to help develop new treatments for sepsis. We will do this through the UK Genomic Advances in Sepsis study, applying big data (-omics) and clinical experimental medicine approaches.Where will the work be done? The work will be undertaken at the University of Oxford, Sanger Institute and Imperial College.When will the work be carried out? The work will be undertaken from 2020 to 2024.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1101/2022.08.07.22278495
发表时间: 2022-08
期刊:
影响因子: --
作者: [Yuxin Mi;K. Burnham;P. Charles;R. Heilig;I. Vendrell;J. Whalley;H. Torrance;D. Antcliffe;S. May;M. Neville;Georgina;Berridge;P. Hutton;Cyndi Goh;J. Radhakrishnan;A. Nesvizhskii;Fengchao Yu;E. Davenport;S. McKechnie;R. Davies;D. O'Callaghan;P. Patel;F. Karpe;A. Gordon;G. Ackland;Charles Hinds;R. Fischer;J. Knight]
通讯作者: Yuxin Mi;K. Burnham;P. Charles;R. Heilig;I. Vendrell;J. Whalley;H. Torrance;D. Antcliffe;S. May;M. Neville;Georgina;Berridge;P. Hutton;Cyndi Goh;J. Radhakrishnan;A. Nesvizhskii;Fengchao Yu;E. Davenport;S. McKechnie;R. Davies;D. O'Callaghan;P. Patel;F. Karpe;A. Gordon;G. Ackland;Charles Hinds;R. Fischer;J. Knight
DOI: 10.1097/sla.0000000000006050
发表时间: 2024-03-01
期刊: Annals of surgery
影响因子: 9
作者: []
通讯作者:
DOI: 10.1101/2022.07.12.22277463
发表时间: 2022-07
期刊:
影响因子: --
作者: [D. Antcliffe;Yuxin Mi;S. Santhakumaran;K. Burnham;Toby Prevost;Josie K Ward;Timothy Marshall;Claire Bradley;F. Al-Beidh;Paula;Hutton;S. McKechnie;E. Davenport;Charles Hinds;D. F. Mcauley;Manu Shankar-Hari;Anthony C Gordon;Julian Knight]
通讯作者: D. Antcliffe;Yuxin Mi;S. Santhakumaran;K. Burnham;Toby Prevost;Josie K Ward;Timothy Marshall;Claire Bradley;F. Al-Beidh;Paula;Hutton;S. McKechnie;E. Davenport;Charles Hinds;D. F. Mcauley;Manu Shankar-Hari;Anthony C Gordon;Julian Knight
An immune dysfunction score for stratification of patients with acute infection based on whole blood gene expression
基于全血基因表达的急性感染患者分层免疫功能障碍评分
DOI: 10.1101/2022.03.17.22272427
发表时间: 2022
期刊:
影响因子: --
作者: [Cano-Gamez E]
通讯作者: Cano-Gamez E
6
    An immunogenetic approach to guide the need for booster shots and combat immune failure in SARS-CoV-2 vaccine response
    • 批准号:
      MR/W020629/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $125.82万
    • 财政年份:
      2021
    • 负责人:
      Julian Knight
    • 依托单位:
    Application of multiscale algebra and topology to understanding heterogeneity in the immune response to SARS CoV 2 infection
    • 批准号:
      EP/W01484X/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $23.25万
    • 财政年份:
      2021
    • 负责人:
      Julian Knight
    • 依托单位:
    FINE MAPPING OF REGULATORY GENETIC VARIATION INVOLVING COMMON AUTOIMMUNE DISEASE ASSOCIATED HAPLOTYPES IN THE HUMAN MHC
    • 批准号:
      G1001708/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $45.77万
    • 财政年份:
      2011
    • 负责人:
      Julian Knight
    • 依托单位:
    海外基金